Asset
ALDOXORUBICIN
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02200757 | phase2 | completed | 2015-04-20 | 2017-05-15 | ImmunityBio, Inc. | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer |
| NCT01673438 | phase1 | completed | 2012-07-01 | 2014-04-01 | ImmunityBio, Inc. | Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors |
| NCT02049905 | phase3 | completed | 2014-01-01 | 2017-05-01 | ImmunityBio, Inc. | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas |
| NCT01580397 | phase2 | completed | 2012-05-16 | 2013-05-13 | ImmunityBio, Inc. | Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer |
| NCT01514188 | phase2 | completed | 2012-01-11 | 2014-04-09 | ImmunityBio, Inc. | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma |
FDA applications (0)
This company has no applications containing this asset.